Fat-1 Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease and Atherosclerosis through Promoting the Nuclear Localization of PPARα in Hamsters.

Interestingly, although no statistical difference was observed, an increasing trend of hepatic n-3/n-6 ratio was noted in LDLR −/− hamsters treated with AAV9-Fat-1 (Fig. 7 M).

also in 63,971 other papers

Similarly, Picrosirius Red staining and CD68 immunofluorescence staining also showed a trend of decrease in fibrosis or inflammation in the AAV9-Fat-1-treated group, respectively (Fig. 7 F and H).

also in 53,322 other papers